

**MEDADVISOR LIMITED**  
**Chairman's Address**  
**AGM 24 October 2017**

Good morning and welcome to this year's annual general meeting. I am delighted to report on the progress and recent achievements of MedAdvisor.

FY17 was an incredibly busy year for MedAdvisor, both operationally and corporately. We made two acquisitions - Healthnotes and OzDocsOnline. Each has strengthened our offering and solidified our position as the leading health management solution in Australia. Healthnotes bought a number of technical capabilities and proprietary technologies that enabled us to launch our new PlusOne platform for pharmacies, which is delivering significant value to our pharmacy network.

The capabilities we gained from acquiring OzDocsOnline enable patients to book doctor appointments online, and to access eConsultations, pathology results and specialist referrals....bringing ultimate convenience to our users.

Our patient user base grew by over 350% this year to over 830k patients, and after the first quarter of FY18, is over 900k. We have a significant opportunity to expand this further. Close to 50% of Australian pharmacies are using our technology and we have estimated a further 5 million plus patients within our pharmacy network with a chronic disease that would benefit immensely from using the MedAdvisor application. Our sales and support teams continue to work closely with our pharmacy partners to help drive customers to the platform and our partnerships with national disease state groups and not for profits continue to deliver user growth.

I am enthused by the opportunities that exist in the overseas markets that we are targeting, where we aim to be the 'go to' application for medication management and convenience. Increasing the connectivity between doctors, pharmacies and patients will result in patients receiving better care with the added convenience of being able to order their medications online and skip the queue for collection.

The US and UK markets are significant growth prospects for MedAdvisor. Each has a large patient population, rising health care costs, and a more concentrated pharmacy market that makes them highly attractive.

We're working closely with our highly experienced advisors in the UK and US, Mr Jamal Butt and Mr Keith Kiarsis, to assist in our market entry strategy. As we look to enter these markets it is important that we harness the local knowledge and expertise of our advisors to develop and evaluate the most appropriate entry model.

Many of you will already be aware that we have welcomed EBOS as a strategic partner and investor in the business. We are delighted that a major industry player has recognised deep value in MedAdvisor. The \$9.5 million investment, at a 44% premium to the last capital raise 12 months prior, is a significant validation of the platform and the further growth opportunity and potential they see in the business.

EBOS is a multibillion dollar business providing products and services to the healthcare industry. We have identified strategic opportunities for us to work together and have signed commercial agreements with three of its subsidiaries, which our CEO will talk to in more detail during the presentation. Each of these will bring a wealth of benefits to the

business, including expansion of the patient user base, our pharmacy network and opportunities to enter new market segments, develop new offerings and new revenue streams.

We are well funded to drive our expansion initiatives and execute the integration, development and optimisation that will be required.

We are fully funded to reach domestic breakeven regardless of our international expansion activities and scoping and planning which is factored into our internal budgets. Our revenue profile domestically continues to grow and we are delighted to be building profitable businesses with EBOS.

MedAdvisor's aim is to increase convenience for consumers and everything we do has this ethos in mind. The healthcare system is complex and managing your health can be a challenge, particularly with time so often becoming a scarce commodity.

During the year we welcomed 24 new team members, which includes 15 outstanding people from Healthnotes to our team.

Mr Ashley Falting and Mr Saurabh Mishra joined the management team with the acquisition of Healthnotes. We've been delighted to have their expertise and industry knowledge on board. We also welcomed Dr David Chatterton as Chief Technology Officer and Mr Simon Chamberlain as General Manager - Product & Strategy. Saurabh, David and Simon are playing vital roles in our domestic and international growth strategies. And of course our two local advisors Mr Jamal Butt in the UK and Mr Keith Kiarsis in the US.

Our focus is squarely set on seeking further growth domestically and internationally. We have in place a great foundation underpinned by world-class technology, a wonderful team and sustainable business model. This year will be another of milestones, achievements and growth.

Thank you for your continued support and commitment to MedAdvisor.

***Peter Bennetto***

***Chairman***

***Melbourne 24 October 2017***



## MedAdvisor Limited

ACN 145 327 617  
Level 4  
969 Burke Road  
Camberwell VIC 3124

phone +61 3 9095 3036  
fax: +61 3 9882 3317  
email: [corporate@medadvisor.com.au](mailto:corporate@medadvisor.com.au)  
PO Box 8225 Camberwell North VIC 3124

24 October 2017

Company Announcements Office  
ASX Limited  
Electronic Lodgement System

### Results of MedAdvisor Limited [ASX:MDR] – Annual General Meeting

The Directors of MedAdvisor Limited (Company) are pleased to announce that at the Annual General Meeting of Shareholders held today, all resolutions put to the meeting were passed unanimously by a show of hands.

In accordance with Section 251AA (2) of the Corporations Act 2001 and Listing Rule 3.13.2, the Company hereby provides the following information on proxy votes:

Resolution	For	Against	Abstain	Excluded	Total
1. Adoption of Remuneration Report	206,550,130	1,127,758	5,704,564	111,330,833	324,713,285
2. Re-election of Director – Mr Peter Bennetto	318,211,036	812,837	5,689,412	-	324,713,285
3. Re-election of Director – Ms Sandra Hook	318,173,158	850,715	5,689,412	-	324,713,285
4. Approval of 10% Placement Capacity	320,893,642	2,593,179	1,165,858	-	324,713,285

Yours Sincerely,  
Peter Bennetto  
Chairman